Alessandro Tancredi

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

Dna Damage Response

Transcription Factor

Binding Protein

Top Venues

Cell death & disease

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle Claudine Buri, Rémy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E Hegi
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. Cell death & disease 13 (12) (2022)
Lea Beltzig, Christian Schwarzenbach, Petra Leukel, Katrin B M Frauenknecht, Clemens Sommer, Alessandro Tancredi, Monika E Hegi, Markus Christmann, Bernd Kaina
Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers 14 (9) (2022)
Girieca Lorusso, Christof B Wyss, François Kuonen, Nicola Vannini, Clotilde Billottet, Nathalie Duffey, Raphael Pineau, Qiang Lan, Pratyaksha Wirapati, David Barras, Alessandro Tancredi, Ruth Lyck, Hans-Anton Lehr, Britta Engelhardt, Mauro Delorenzi, Andreas Bikfalvi, Curzio Ruegg
Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation. Science translational medicine 14 (661) (2022)
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle Claudine Buri, Rémy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E Hegi
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. Cell death & disease 13 (12) (2022)
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle Claudine Buri, Rémy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E Hegi
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. Cell death & disease 13 (12) (2022)
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle Claudine Buri, Rémy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E Hegi
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. Cell death & disease 13 (12) (2022)